## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($86.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Pacer Advisors Inc. Cuts Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20260101T111312 | Neutral | Relevance: 100%
- Pacer Advisors Inc. significantly reduced its stake in Zimmer Biomet Holdings, Inc. by 98.0% in Q3, selling 844,530 shares and retaining 16,935 shares valued at $1.668 million. Despite mixed analyst ratings, the consensus is a "Hold" with an average price target of $107.50. Zimmer Biomet recently reported Q3 EPS of $1.90, exceeding estimates, and announced a quarterly dividend.

**2. Calamos Advisors LLC Has $4.66 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20260101T101452 | Somewhat-Bullish | Relevance: 100%
- Calamos Advisors LLC reduced its stake in Zimmer Biomet Holdings, Inc. by 63.7% in the third quarter, selling 83,000 shares and retaining 47,324 shares valued at $4.66 million. Meanwhile, other institutions like Royal Bank of Canada and Vident Advisory LLC increased their holdings, contributing to 88.89% institutional ownership. Zimmer Biomet recently beat EPS estimates, reported strong revenue growth, and announced a quarterly dividend, while analysts maintain a "Hold" rating with an average price target of $107.50.

**3. Dental Implants Market Booming with Rapid Growth Through 2032 |**
- Source: openPR.com | 20260102T110900 | Bullish | Relevance: 83%
- The dental implants market is projected to grow from USD 5.54 billion in 2025 to USD 9.07 billion by 2032, exhibiting a CAGR of 7.3%. This growth is driven by rapid innovation, rising investment, and shifting regional dynamics. The market research report provides insights into market segmentation, competitive landscape, and key players like DENTSPLY Sirona and Straumann AG, offering strategic intelligence for decision-makers.

**4. Surgical Robotics Market to Reach US$ 15.25 Billion by 2033**
- Source: openPR.com | 20260102T072601 | Bullish | Relevance: 65%
- The global surgical robotics market is projected to grow from US$ 5.84 billion in 2024 to US$ 15.25 billion by 2033, driven by increasing preference for minimally invasive surgeries, technological advancements, and the rising burden of chronic diseases. North America currently leads the market with a 42% share, while the Asia Pacific region is expected to show high growth. Key players include Intuitive Surgical, Stryker Corporation, and CMR Surgical.

**5. NeuroOne Medical Technologies Corp (NMTC) Q4 2025 Earnings Call Highlights: Record Revenue ... By GuruFocus**
- Source: Investing.com Canada | 20260102T080913 | Neutral | Relevance: 64%
- NeuroOne Medical Technologies Corp (NMTC) reported a significant increase in product revenue of 163% to $9.1 million for fiscal year 2025, alongside improved gross margins and reduced operating expenses. The company also secured FDA 510(k) clearance for its OneRF trigeminal nerve ablation system and strengthened its balance sheet with an $8.2 million capital raise. Despite these successes, NMTC faces challenges such as NASDAQ compliance, obtaining ISO 13485 certification, and establishing strategic partnerships for its new platforms.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Baird | $100 | $117 | -15% |
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Baird | down | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 7.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +2.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Forward P/E 10.6x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.8B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 10.6 |
| Current P/E | 11.0 |
| YoY Growth | 4.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.3% to 0.7% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.3pp (needs >3.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 42. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.74% (CS: 51) | Neutral |
| RSI_14 | 42.5 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 0.964x | Below |
| vs SMA200 | 0.923x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $90.02
- **Stop Loss:** $86.44 (4.0% risk)
- **Target:** $93.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 402
- **Position Value:** $36,188.04
- **Portfolio %:** 36.19%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*